AB0195 PHARMACOKINETIC AND PHARMACODYNAMIC EVALUATION OF A PROPOSED BIOSIMILAR MSB11456 VERSUS BOTH THE US-LICENSED AND EU-APPROVED TOCILIZUMAB: RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, SINGLE-DOSE TRIAL IN HEALTHY ADULTS
Schwabe, C., Wynne, C., Illes, A., Ullmann, M., Vincent, E., Ghori, V., Petit-Frere, C., Racault, A. S., Morin, I.
Published in Annals of the rheumatic diseases (01.06.2021)
Published in Annals of the rheumatic diseases (01.06.2021)
Get full text
Journal Article